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The World Health Organisation’s (WHO) recommendation of life-long antiretroviral 
prophylaxis to pregnant women who are positive for Human Immunodeficiency Virus (HIV) 
has increased HIV-exposed but uninfected infants. These infants are more likely to be born 
premature and small for their gestational age. They require prolonged hospitalisation, making 
them susceptible to nosocomial infections. The study aimed to determine the organisms causing 
infections in these HIV-exposed newborns, their susceptibility profiles, risk factors and 
outcome compared to their unexposed counterparts.  
 
Methods: 
This prospective descriptive study was conducted at King Edward VIII Hospital in Durban 
between January 2014 and December 2019. Laboratory and clinical data of neonates admitted 
to the neonatal unit with possible bacterial infection were collected. The organisms and their 




A total of 276 neonates were included in the final analysis, 50.7% of which were HIV-exposed. 
Group B Streptococcus was the predominant organism isolated in the HIV-exposed neonates 
in early-onset sepsis while Group B Streptococcus and Klebsiella pneumoniae in the HIV-
unexposed. Gram-negative bacilli accounted for 65.8% of the bloodstream organisms causing 
late-onset sepsis of which Klebsiella pneumoniae was the most common Gram-negative 
pathogen with 61% being extended-spectrum β-lactamase (ESBL) producing and 23% 
carbapenemase-producing. Antimicrobial resistance was common in endotracheal aspirates 
which included ESBL producing and carbapenemase resistant Klebsiella pneumoniae, ESBL 
producing E. coli and multidrug-resistant (MDR). Acinetobacter spp. as well as Gram-positive 
bacteria that were resistant to Cloxacillin. HIV-exposure was found to be associated low birth 
weight (p <0.001).  
 
Conclusion: 
Group B Streptococcus remains the most common pathogen causing early-onset sepsis in both 
HIV-exposed and unexposed neonates and is covered by the current empiric antibiotics 
x 
prescribed in the unit. Resistant gram-negative bacteria caused the majority of the episodes of 
late-onset sepsis in both groups. A review of antibiotic treatment for late-onset sepsis and 






CHAPTER ONE: INTRODUCTION 
1.1 Background: 
KwaZulu-Natal is one of the provinces with the highest seroprevalence of HIV (human 
immunodeficiency virus) among pregnant women (Naidoo, Sartorius & Tshimanga-Tshikala, 
2016). Administration of combined antiretroviral agents in HIV-infected pregnant women has 
markedly reduced the risk of mother-to-child transmission (MTCT) of the virus, leading to an 
increasing number of HIV-exposed uninfected (HEU) infants (Evans, Jones & Prendergast, 
2016). These infants are known to have more severe disease, more hospitalisations and higher 
mortality than HIV-unexposed (HU) children (Slogrove, Goetghebuer, Cotton, Singer & 
Bettinger, 2016). 
 
The Zimbabwe Vitamin A for Mothers and Babies Project (ZVITAMBO) trial was the first 
study to demonstrate higher mortality and morbidity in HEU infants definitively (Slogrove et 
al., 2016). This study had the largest cohort of HIV-exposed uninfected and HIV-unexposed 
infants. The most common causes of death in HEU infants were acute respiratory infections 
(57.7%), diarrheal illness or dysentery (16.1%), malnutrition (13.3%), sepsis (6.0%), and 
meningitis (4.8%). The highest absolute mortality for HEU infants was in the neonatal period. 
 
Neonatal infections cause nearly a quarter (23%) of all neonatal deaths, with neonatal sepsis 
accounting for 15% of these deaths (Folgori et al., 2017b). There is a paucity of data from low-
income and middle-income countries concerning pathogen distribution, epidemiology and 
resistance patterns unlike the well-established surveillance networks in high-income countries 
(Okomo et al., 2019). Although the risk of mortality from neonatal infections is high in sub-
Saharan Africa, there is a substantial gap in aetiology-specific data (Okomo et al., 2019). 
 
Neonatal sepsis is defined as a systemic infection occurring in infants during the first 28 days 
of life (Simonsen, Anderson-Berry, Delair & Davies, 2014). Sepsis occurring in the first three 
days of life is defined as early-onset sepsis (EOS) and beyond three days as late-onset sepsis 
(LOS). Epidemiological studies have observed a reduction in EOS, while LOS incidence has 
been increasing (Dong & Speer, 2015). Group B Streptococcus (GBS) has historically been the 
predominant organism causing early-onset sepsis in neonates. With the introduction of prenatal 
screening and intrapartum prophylaxis, current trends show a decrease in GBS frequency (Dong 
& Speer, 2015).  
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Implementing interventions to improve the survival of premature infants has led to the 
incidence of LOS increasing (Dong & Speer, 2015). Prolonged hospitalisation of these 
premature and low birth weight infants has led to a change in the microbial characteristics of 
LOS globally. Common pathogens for late-onset sepsis include coagulase-negative 
staphylococcus (CoNS), Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, 
gram-negative bacilli, and Candida. 
 
The incidence of severe infections caused by multidrug-resistant (MDR) pathogens is currently 
rising worldwide. An increasing number of neonates and children with serious bloodstream 
infections due to resistant bacteria are being reported (Folgori & Bielicki, 2019). Multi-drug 
resistant is defined as acquired non-susceptibility to at least one agent in three or more 
antimicrobial categories. Extensively drug-resistant (XDR) is defined as non-susceptibility to 
at least one agent in all but two or fewer antimicrobial categories (Magiorakos et al., 2012). 
 
Antimicrobial resistance (AMR) is responsible for approximately 30% of neonatal deaths due 
to sepsis, globally (Laxminarayan et al., 2016). These multidrug-resistant pathogens have 
become a challenge for both high and low-middle income countries and affect predominantly 
premature infants (Folgori, Bielicki, Heath & Sharland, 2017a).  
 
The epidemiology of neonatal sepsis is changing, and increases in antimicrobial resistance is a 
global concern. The Delhi Neonatal Infection Study (DeNIS) followed up a cohort of 88 636 
newborn infants in three large hospitals in Delhi (Agarwal, Sankar, Health & Centre, 2016). It 
represents one of the largest studies to date of neonatal sepsis and resistance in the Indian 
subcontinent. The study showed high rates of Acinetobacter spp and coagulase-negative 
staphylococcal infections among the pathogens. 
 
Nearly half of the pathogens that cause severe neonatal bacterial infections are resistant to the 
first-line (ampicillin or penicillin, and gentamicin) and second-line (third-generation 
cephalosporins) WHO-recommended treatments (Folgori et al., 2017b). Due to resistant 
pathogens, infections necessitate early use of broad-spectrum antibiotics due to the 
ineffectiveness of recommended first-line antibiotics (Dramowski et al., 2020).  
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A few studies have reported on AMR from different neonatal units around the country. (Ballot 
et al. (2019) described an increase in multi-drug resistant organisms causing bloodstream 
infections (BSI) in a neonatal unit in Johannesburg, South Africa (Ballot et al., 2019). An 
observational study in the NICU (neonatal intensive care unit) of a regional hospital in the 
northern part KwaZulu-Natal found that of the144 neonates that developed a nosocomial 
infection, Klebsiella pneumoniae was the most prevalent organism followed by Staphylococcus 
aureus and Acinetobacter baumanni (Rameshwarnath & Naidoo, 2018). However, the real 
burden of antimicrobial resistance in South Africa is unknown due to the lack of national 
programmes for neonatal infection surveillance (Dramowski et al., 2020). Regular monitoring 
and bench-marking causes of neonatal sepsis and their susceptibility patterns are vital to update 
policies and improve clinical practices (Giannoni et al., 2018). 
 
1.2 Aim: 
The study aimed to: 
 identify risk factors that are associated with neonatal infections in HIV-exposed and 
unexposed newborns at the King Edward VIII Hospital Neonatal Unit; 
 establish the aetiology and susceptibility patterns of organisms responsible for neonatal 
infections; and  
 document the outcome of neonates with proven infection. 
 
1.3 Objective: 
 To assess the risk factors associated with neonatal sepsis; 
 To investigate the organisms isolated from blood cultures, respiratory and cerebrospinal 
fluid samples responsible for neonatal sepsis in the unit;  
 To establish the antibiotic susceptibility profile of these organisms to antimicrobial 
agents used; and 
 To determine the outcome of these infections – the primary outcome being mortality 
and secondary being morbidity.
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CHAPTER 2: LITERATURE REVIEW 
2.1 Neonatal sepsis  
Sepsis remains the leading cause of neonatal mortality and morbidity (Giannoni et al., 2018). 
Neonates are prone to infections as their immune systems are still developing and not as robust 
(Basha, Surendran & Pichichero, 2014). Neutrophils, which are a major component of the 
innate immune system, are immature and have reduced phagocytic and chemotaxis ability. 
Neonatal antigen-presenting cells, mainly monocytes and dendritic cells, have impaired activity 
and are found in low numbers (Basha et al., 2014). The adaptive immune system is also 
underdeveloped due to reduced numbers of neonatal lymphocytes, B-cell immaturity and 
cytokine production being downregulated. HIV-exposed neonates are shown to have low 
concentrations of maternally derived antibodies at birth and numerous T-cell abnormalities, 
including low CD4 counts (Evans et al., 2016). 
 
The incidence of neonatal sepsis varies in different geographic regions depending on the 
availability of resources, risk factors for both mother and infant, and prevention strategies 
(Giannoni et al., 2018). EOS presents within 72 hours after birth, affecting 0.5-1 out of 1000 
infants in high-income countries, with a case fatality rate of 10%-15% (Giannoni et al., 2018). 
LOS is characterized by onset beyond 72 hours after birth with reported rates of hospital-
acquired LOS as high as 40% in extremely preterm newborns (Giannoni et al., 2018). 
 
Neonatal sepsis can range from subclinical infection to severe systemic disease. These 
infections include common childhood infections like pneumonia, meningitis and diarrheal 
disease, but morbidity and mortality are reported to be higher in HIV-exposed infants (Slogrove 
et al., 2016). Pathogens are acquired intrauterine, during the delivery process or in the post-
natal period, and the clinical manifestations depend on pathogens and routes of infection.  
 
2.2 Early Onset Sepsis vs Late-Onset Sepsis 
Early-onset sepsis is caused by maternally transmitted pathogens and occurs during the 
intrapartum period or just before delivery and reflects transplacental or ascending infections 
from the maternal genital tract (Simonsen et al., 2014). The bacteria involved are part of the 
maternal gastrointestinal and genitourinary tract's normal bacterial flora, resulting in 
subsequent colonisation and the fetus's infection (Cortese et al., 2016). Newborns exposed to 
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these bacteria can become ill due to aspiration of infected amniotic fluid in utero or during the 
delivery process. Risk factors for infection include chorioamnionitis, prolonged rupture of 
membranes and inadequate intrapartum antibiotic prophylaxis (Zea-Vera & Ochoa, 2015). 
 
LOS is caused by microorganisms acquired from caregivers and the environment. Premature 
infants that require prolonged hospitalisation are at risk, especially in those with very low birth 
weight (VLBW) (Dong & Speer, 2015). Risk factors include underlying respiratory and 
cardiovascular diseases and strategies implemented to improve the premature neonate's survival 
like the use of invasive devices, endotracheal intubation, vascular catheterization and prolonged 
antibiotics (Dong & Speer, 2015) The causative pathogens characteristically represent 
colonisation with the microflora of the nosocomial environment. Hospital-acquired LOS, 
therefore, represents a preventable disease. It may change over time within the same hospital 
due to patients' demographic characteristics, microflora colonisation of the nosocomial 
environment, and antibiotic use (Dong & Speer, 2015).  
 
Neonatal meningitis is a life-threatening disease that develops following primary bacteraemia 
with secondary spread to the central nervous system (Bedetti et al., 2019). Mortality occurs in 
approximately 10% of affected neonates while 20–50% of the survivors develop cognitive 
deficiencies, motor abnormalities and sensory impairments (Gordon, Srinivasan & Harris, 
2017). The causes of neonatal meningitis in the high-income countries are GBS, Escherichia 
coli, Listeria monocytogenes, Gram-negative enteric bacteria and Streptococcus pneumoniae 
(Furyk, Swann & Molyneux 2011). In low- and middle-income countries, Gram-negative 
bacilli such as Klebsiella pneumoniae and E. coli appear to be more important pathogens, 
especially in LOS (Khalessi & Afsharkhas, 2014). 
 
Neonatal pneumonia is defined as a pulmonary infection occurring within the first 28 days of 
life and a common problem in sub-Saharan Africa (Green & Kolberg, 2016). Risk factors for 
neonatal pneumonia include prolonged rupture of membranes, prematurity, meconium 
aspiration syndrome and mechanical ventilation. With preterm birth complications and 
intrapartum complications, pneumonia remains one of the leading causes of neonatal mortality 
(Green & Kolberg, 2016). Aiken reported significantly higher rates of congenital pneumonia 
based on lung pathology in neonates of HIV-infected mothers (Aiken, 1992).  
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The causes of pneumonia in the neonatal period include bacteria and viruses. Perinatally, 
pneumonia is caused by vertically transmitted organisms such as GBS and E. coli (Green & 
Kolberg, 2016). Ureaplasma urealyticum and Mycoplasma hominis are being increasingly 
recognised as organisms that cause congenital pneumonia (Green & Kolberg, 2016). Common 
viral causes include herpes simplex virus (HSV) and respiratory syncytial virus (RSV). Viral 
infections are more often acquired via nosocomial transmission from staff and infected patients 
in the neonatal unit, but HSV is acquired during delivery through an infected maternal genital 
tract (Green & Kolberg, 2016). 
 
Mechanical ventilation is a major risk factor for the development of LOS. Pneumonia in 
mechanically ventilated patients is due to the introduction of organisms into the trachea via the 
microaspiration of gastric and oropharyngeal secretions. The oropharyngeal flora may be 
colonised with the neonate’s endogenous flora or exogenously from the intensive care 
environment, from the hands of healthcare workers or contaminated ventilator circuits and 
humidifiers (Safdar, Crnich & Maki, 2005). This provides a potential route of entry for hospital-
acquired bacteria.  
 
Ventilation-associated pneumonia (VAP) is a complication of mechanical ventilation and one 
of the most common hospital-acquired infections in the neonatal ICU (Cernada, Brugada, 
Golombek & Vento, 2014). The incidence of VAP in neonates is influenced by the gestational 
age and income level of the country, with an incidence of 2.7 to 10.9 episodes per 1000 
ventilator days reported from high-income countries and higher rates of 37.2 cases per 1000 
ventilator days in low- and middle-income countries (Cernada et al., 2014). The pathogens 
implicated in VAP also vary according to the geographic region. Gram-negative bacilli were 
found to be exceptionally high in Asia while in Europe and North America, Staphylococcus 
aureus was predominant (Aelami, Lotfi & Zingg, 2014). Therefore, knowledge about the 
commonest pathogens colonising trachea in mechanically ventilated patients is important at the 
institute level.  
 
2.3 Organisms causing Early Onset Sepsis 
Group B Streptococcus has historically been the predominant organism causing early-onset 
sepsis in neonates (Cortese et al., 2016). Group B Streptococcus is a Gram-positive bacterium 
that primarily colonises both the gastrointestinal and genital tracts of healthy women (Mukesi 
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et al., 2019). Twenty to forty percent of healthy women are asymptomatically colonised with 
GBS. Newborns are at risk of acquiring GBS during labour and delivery as they swallow or 
aspirate the bacterium while passing through the birth canal. Disease manifestations include 
meningitis, pneumonia, sepsis, and can lead to long-term disabilities and death (Gizachew et 
al., 2019). Cutland et al. (2015) evaluated invasive GBS disease in young infants in a high 
maternal HIV prevalence setting and found the incidence of GBS disease greater in HIV-
exposed than unexposed infants (Cutland et al., 2015). Serotype distribution was similar in both 
groups with serogroup III, causing more meningitis and serotype V bacteraemia (Cutland et al., 
2015). 
 
Maternal antibiotic prophylaxis for GBS has led to an increase in Gram-negative organisms, 
causing sepsis. Escherichia coli is the second leading cause of EOS in neonates, accounting for 
about 24% of all EOS episodes (Simonsen et al., 2014). Like other coliforms, E. Coli colonises 
the maternal recto-vaginal area, and the newborn can acquire it during delivery. Very low birth 
weight (VLBW) infants showed higher E. coli infection rates in prospective surveillance of 
EOS by Stoll et al. (2011). Rates of infection with E. coli was higher than GBS in neonates 
weighing <2500g while in infants with a birth weight of >2500g, GBS rates were higher (0.35 
vs 0.07 per 1000 Live births) (Stoll et al., 2011). 
 
The remaining causes of EOS include Staphylococcus aureus, Enterococcus faecalis, 
Enterococcus faecium, Listeria monocytogenes and other gram-negative bacilli (Simonsen et 
al., 2014). Streptococcus pyogenes and Streptococcus viridans, Streptococcus pneumoniae, H. 
Influenzae and Pseudomonas aeruginosa are uncommon sources for EOS, but several reports 
have documented neonatal infections by these agents (Coetzee, Mbowane & de Witt, 2017). 
 
A recent study by Velaphi et al. (2019) on the aetiology and incidence of EOS in neonates from 
a large academic hospital in Soweto, South Africa found that the most common organisms 
isolated were Gram-positive bacteria. Unlike reports from other sub-Saharan African countries, 
the most common organism in that study was GBS instead of Staphylococcus aureus. Gram-
negative bacteria accounted for only 25% of EOS overall, with 8% being E. coli and 
Acinetobacter species isolated in 4% (Velaphi et al., 2019). 
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2.4 Organisms causing Late-Onset Sepsis 
The development of LOS is inversely related to gestational age and birth weight. 
Epidemiological data on very low birth weight (VLBW) infants shows that the predominant 
pathogens are Coagulase-negative staphylococci, followed by Gram-negative bacilli and fungi 
(Dong & Speer, 2015). Coagulase-negative staphylococci have emerged as the predominant 
pathogen of LOS. It accounts for 53.2%–77.9% of LOS in industrialised countries and 35.5%–
47.4% in some low- and middle-income regions (Dong & Speer, 2015). The main gram-
negative bacilli responsible for neonatal LOS include Escherichia coli, Klebsiella spp, 
Enterobacter spp. and Pseudomonas spp. In some regions, Candida spp. is reported to be one 
of the major pathogens for LOS (Dong & Speer, 2015). Due to the difficulties in prompt 
diagnosis of LOS and the high risk of mortality and long-term neurodevelopmental sequelae, 
empirical antibiotic treatment is initiated on suspicion of LOS. 
 
2.5 Diagnosis of Neonatal Sepsis 
The clinical diagnosis of neonatal sepsis is difficult as signs and symptoms are nonspecific and 
unreliable in a newborn. The use of maternal intrapartum antimicrobial prophylaxis can confirm 
sepsis in the neonate challenging (Iroh Tam & Bendel, 2017). Laboratory diagnosis is limited 
due to the low sensitivity of most specimens. The gold standard for microbiological diagnosis 
for neonatal sepsis has historically relied on culture from a sterile site, including blood, 
cerebrospinal fluid or urine (Coetzee et al., 2017). Blood culture positivity is affected by several 
factors. The current recommended minimal blood volume inoculated is 1ml, and the sensitivity 
is reported to decrease by 10% to 40% when 0.5 ml is inoculated (Reyes, 2018). Culture 
negative results may also result from prior maternal antimicrobial treatment and intermittent or 
low-density bacteraemia found in neonates (Zea-Vera & Ochoa, 2015). 
 
Endotracheal aspirates are readily obtained from ventilated patients, but sensitivity and 
specificity are low (Coetzee et al., 2017). Clinicians often use semi-quantitative neutrophil 
counts and quantitative bacterial culture results from endotracheal aspirates in conjunction with 
clinical and radiographic signs to diagnose VAP (Ergenekon & Çataltepe, 2020). Although a 
negative tracheal aspirate culture has a high negative predictive value for excluding VAP, 
positive cultures may identify the organisms that are colonising the airway (Coetzee et al., 
2017). Patil (2014) looked at tracheal colonization in 100 mechanically ventilated patients for 
seven days doing tracheal aspirates on Day 1, 4 and 7. They noted that the isolation rate 
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increased with increased ventilation duration from 18.6% to 44.6% (Patil, 2014). Among the 
positive cultures, Pseudomonas aeruginosa was the most commonly isolated organism 
(37.4%). This was followed by Klebsiella pneumoniae (28.5%), Staphylococcus epidermidis 
(14.7%) and Staphylococcus aureus (4.36%). The isolation rate of Pseudomonas aeruginosa 
and Klebsiella pneumoniae increased with the duration of ventilation, but a significant increase 
was seen with Coagulase negative staphylococcus (Journal & Science, 2014). 
 
Bacterial meningitis causes high mortality and morbidity, and positive CSF culture is the gold 
standard for its diagnosis. Bedetti et al. reported that nearly one-quarter had concurrent 
meningitis in septic neonates with positive blood cultures (Bedetti et al., 2019). However, CSF 
culture is of poor sensitivity; therefore, clinicians rely on other CSF parameters like CSF 
glucose, white blood cell (WBC) count and protein (Bedetti et al., 2019). 
 
The use of molecular diagnostics has been evaluated for the diagnosis of neonatal sepsis. These 
predominantly amplification methods, such as polymerase chain reaction (PCR) are more rapid 
and sensitive than culture-based methods (Iroh Tam & Bendel, 2017). They carry promise in 
neonatal infections where intrapartum exposure to antimicrobials, low-density bacteremia and 
culture-negative sepsis is common. Velaphi et al. (2019) evaluated the combination of blood 
culture and a polymerase chain reaction (PCR)-based test to determine the incidence and 
aetiology of  EOS. The molecular assay used identified more organisms from blood culture, 
including non-culturable organisms like Ureaplasma species. However, a combination of blood 
culture and this assay improved the detection of organisms in neonates with sepsis (Velaphi et 
al., 2019). 
 
2.6 Neonatal HIV Infection 
Maternal HIV infection can have severe adverse effects on pregnancy. It leads to preterm 
delivery, low birth weight infants at risk for postnatal morbidity and mortality (Xiao et al., 
2015). A significant finding by Naidoo et al. (2016) was that HIV-positive mothers were four 
times more likely to have preterm delivery than their HIV-negative counterparts (OR 4.09, 95% 
CI: 1.37–12.17) (p = 0.010) (Naidoo et al., 2016). HEU infants experience numerous exposures 
during fetal and early life that could increase their vulnerability to infectious diseases during 
infancy compared to HIV-unexposed infants (Slogrove et al., 2016). Diagnosing and treating 
paediatric HIV infection early, improves morbidity and mortality. Infant mortality is reduced 
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by 76% with early HIV diagnosis and antiretroviral therapy, while the progression of HIV is 
slowed by 75% (Templer et al., 2016).  
 
Early HIV testing in infants is crucial for immediate access to treatment and care programmes. 
Serologic tests are unreliable (Templer et al., 2016). Passively transferred maternal antibodies 
may be detected and may not indicate infant infection. The universal birth HIV PCR testing 
programme was introduced in 2015 by the WHO to diagnose HIV-infected neonates as early 
as possible and initiate ART. Current guidelines recommend antiretroviral drugs to all 
newborns with perinatal exposure to HIV (South African National Department of Health, 
2019). 
 
2.7 Antimicrobial Resistance 
The epidemiology of neonatal sepsis is changing, with resistant infections often occurring in 
the first days of life (Dramowski et al., 2020). A systemic review of studies from sub-Saharan 
Africa and the Indian subcontinent found the incidence of antibiotic resistance among neonates 
ranged from 2.9 (95% CI 1.9–4.2) to 24 (95% CI 21.8–25.7) for 1000 live births (Huynh et al., 
2015). Mortality from drug-resistant bacteria is higher in low- and middle-income countries 
than in high-income countries (Crellen et al., 2019). These infection-attributable deaths affect 
more preterm and low-birthweight neonates (Dramowski et al., 2020). Multi-drug resistant 
gram-positive pathogens include Methicillin-resistant Staphylococcus aureus, Vancomycin-
resistant Enterococcus and penicillin-non-susceptible Streptococcus pneumoniae. These 
infections are being contained by improved infection control measures, development of new 
antibiotics and vaccines (Folgori & Bielicki, 2019). Gram-negative pathogens have been 
reported to have high resistance levels with a large proportion being resistant to the first and 
second-line treatment for neonatal sepsis recommended by the WHO (Folgori & Bielicki, 
2019). These include ESBL- and carbapenemase-producing K. pneumoniae, Acinetobacter 
baumanii, P aeruginosa, and Enterobacter species have been referred to as “ESKAPE” 
pathogens. Greater than 80% of the Acinetobacter spp. in the Delhi Neonatal Infection Study 
were untreatable and pan-resistant with high mortality (Mathur, Li, Folgori, Sharland & Heath, 
2016; Agarwal et al., 2016) 
 
Gram-negative bacteria display antimicrobial resistance by expressing antibiotic-inactivating 
enzymes and non-enzymatic mechanisms such as efflux pumps and alterations by loss of outer 
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membrane porins (Ruppé, Woerther & Barbier, 2015). Resistance to beta-lactam antibiotics (β-
lactams) in Enterobacteriaceae is due primarily to β-lactamase-mediated antibiotic hydrolysis, 
while efflux pumps and porins play a minor role (Gazin et al., 2012). Production of beta-
lactamase may be chromosomally mediated or plasmid-borne where the genes are carried on 
plasmids and transposons (Ruppé et al., 2015). These horizontally transferable genes can also 
carry genes that encode resistance to aminoglycosides and fluoroquinolones (Ruppé et al., 
2015). 
 
Beta-lactamases are divided into four classes based upon their amino acid sequences according 
to the Ambler classification. This is the most widely used classification, and they are divided 
into four classes (A, B, C, and D) (Hall & Barlow, 2005). Extended-spectrum β-lactamases 
(ESBL) belonging to Ambler class A are most abundant and include the sulfhydryl reagent 
variable β-lactamase (SHV), Temoniera β-lactamase (TEM) and cefotaxime-M β-lactamase 
(CTX-M) types. These clinically significant extended-spectrum β-lactamases have spread 
rapidly between Klebsiella pneumoniae, Enterobacter spp. and E. coli and have become 
endemic in many hospitals globally (Ruppé et al., 2015).  
 
Carbapenems remained the last-resort treatment for ESBL related infections. However, its 
increasing use has led to resistance. Mechanisms of carbapenem resistance are in the form of 
porin loss, active expulsion from the periplasmic space and beta-lactamases (Meletis, 2016). 
These carbapenemases are divided into metallo-carbapenemases (zinc-dependent Class B) and 
non-metallo-carbapenemases (zinc independent Class A, C and D) (Lee et al., 2016). The most 
common Enterobacteriaceae exhibiting carbapenem resistance is Klebsiella pneumoniae and 
the class A enzyme K. pneumoniae carbapenemase (KPC), is the most frequent class identified 
worldwide (Lee et al., 2016). Other carbapenemases in this class include IMI (imipenem-
hydrolyzing β-lactamase), NMC-A (not metalloenzyme carbapenemase), SME (Serratia 
marcescens enzyme) and GES (Guiana extended-spectrum) enzymes (Meletis, 2016). 
 
Class B carbapenemases are the metallo-β-lactamases (MBLs) that require zinc for the β-lactam 
hydrolysis and include IMP (active on imipenem), VIM (Verona integron-encoded MBL), and 
New Delhi metallo-β-lactamases (Meletis, 2016). Class C includes AmpC β-lactamase 
enzymes with weak hydrolytic activity against carbapenems, but their resistance is due to the 
added mechanisms of decreased outer membrane permeability and efflux pump (Meletis, 
2016). Ambler class D carbapenemases are oxacillinases OXA (oxacillin-hydrolyzing) which 
12 
can hydrolyze oxacillin and are commonly found in Pseudomonas aeruginosa and 
Acinetobacter spp. (Meletis, 2016). 
 
The geographic distribution of carbapenemases is similar in adult and pediatric populations 
(Chiotos, Han, & Tamma, 2016). The KPC-producing strains account for up to 80% of 
carbapenem resistance in the United States and dominate in Italy, Israel, Greece and Portugal. 
NDM-1 metallo-β-lactamases is endemic in the Indian region and South Asia, while OXA-type 
carbapenemases have been reported in the Middle East, North Africa and is endemic inTurkey 
(Folgori & Bielicki, 2019). 
 
Case reports and case series currently guide treatment for Carbapenemase-producing 
Enterobacteriaceae (CPE) infections in neonates as optimal treatment regimes, and therapeutic 
agents are unavailable (Folgori & Bielicki, 2019). The majority of CPE isolates are resistant to 
the most antibiotic classes. Therefore, Polymyxins have re-emerged as a treatment option for 
serious infections due to carbapenem-resistant organisms (Folgori & Bielicki, 2019). 
Tigecycline has shown to have in vitro activity and has been used when other options are 




CHAPTER THREE: MATERIALS AND METHODS  
This was a retrospective record review conducted in the King Edward VIII Hospital (KEH) 
Neonatal Unit in Durban between July 2014 and December 2019. KEH has 852 beds with 
approximately 22 000 outpatients monthly and provides tertiary services to the whole of the 
KZN province and part of the Eastern Cape. 
 
3.1. Ethics Approval 
The Biomedical Research Ethics Committee of the University of KwaZulu-Natal approved this 
study (BE342/13) (Appendix 5). Gatekeeper Permission was obtained from King Edward VIII 
Hospital (Appendix 6). Permission was obtained from the Department of Health to conduct 
research at King Edward VIII Hospital (Appendix 7). 
 
3.2. Study site  
The study was conducted in the Neonatal Unit at King Edward VIII Hospital, Durban, 
KwaZulu-Natal, South Africa. KEH is a regional hospital that delivers approximately 670 
babies per month. Of these, around 300 are admitted to the nursery for care.  
 
3.3 Study Population  
The study population included neonates admitted to the KEH Neonatal Unit between July 2014 
and December 2019. Neonates with suspected sepsis who had blood culture, CSF, sputum or 
endotracheal aspirates sent to the National Health Laboratory Service (NHLS) microbiology 
laboratory, were included in the study. The clinical data of these patients were reviewed. 
 
3.4. Specimen Collection 
A septic workup was done on any neonate showing signs and symptoms of infection, including 
poor feeding, irritability, lethargy and apnoea. Specimens sent to microbiology laboratory 
included blood cultures, sputum specimens, cerebrospinal fluid if indicated, and endotracheal 
aspirates from ventilated patients. 
 
Blood cultures were obtained from neonates that were admitted to the KEH Neonatal Unit with 
suspected sepsis. One to three millilitres of blood were taken using aseptic technique and 
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inoculated into Paediatric blood culture bottles. These samples were processed at the NHLS 
microbiology laboratory at KEH. The fully automated continuous monitoring blood culture 
system BacT/Alert Microbial Detection System (BioMerieux, France) was used.  
 
Cerebrospinal fluid: All lumbar punctures were performed using aseptic technique and at least 
0.5ml of CSF in a sterile additive-free tube was sent to the laboratory.  
 
Sputum samples or endotracheal aspirates (ETA) from ventilated patients and gastric aspirates 
were sent to the microbiology laboratory. Gastric aspirates were sent for Mycobacterium 
tuberculosis (TB) work-up. 
 
HIV samples were sent for early infant diagnostic testing. Dried Blood Spot for HIV was done 
at the Department of Virology, Inkosi Albert Luthuli Central Hospital. The analysis was done 
in the following categories: HIV-exposed vs HIV-unexposed neonates. 
 
3.5. Laboratory Investigations  
Positive blood cultures were removed from the instrument and microscopy and culture 
performed. Blood cultures were considered negative if there was no growth after continuous 
incubation for up to 7 days.  
 
Gram stain was performed on positive bottles, and Gram-negative bacilli were reported 
immediately to the KEH Neonatal Unit. Identification of bacterial subcultures was performed 
using the automated Vitek 2 AES (BioMerieux, France). Susceptibility results were interpreted 
using the Clinical and Laboratory Standards Institute criteria. 
 
ETAs and sputum specimens were subjected to Gram staining, and the rest of the samples were 
immediately subcultured onto a blood agar plate, a MacConkey plate, and a chocolate agar 
plate. Gastric aspirates were cultured for TB as per laboratory standard operating procedures.  
 
CSF: Once received, the macroscopic appearance was recorded, and the sample was centrifuged 
at 1000 × g for 10-15 min. Microscopy included a cell count and a Gram stain. The sediment 
was then subcultured onto blood, chocolate and MacConkey agar plates and incubated at 37°C 
with 5 per cent CO2 for 18-24 hours. 
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3.5.1 Bacterial Isolation  
Plates were examined for pure cultures or the dominant pathogens. The selected colonies were 
plated out onto blood agar plates to ensure purity. These plates were then incubated at 37 °C 
for 24 hours. A sufficient number of morphologically similar colonies from the purity plate was 
used to prepare a homogenous organism suspension with a density equivalent to the appropriate 
McFarland standard using the VITEK 2 DensiCHEK Plus. The prepared suspension was then 
transferred into the appropriate cards. All fungal cultures were sent to the Mycology laboratory 
at Inkosi Albert Luthuli Central Hospital for further identification and susceptibility testing. 
 
3.5.2 Identification  
The VITEK 2 system uses a fluorogenic methodology for organism identification and a 
turbidimetric method for susceptibility testing. The Advanced Expert System (AES) is a 
database that comprises information on the specific organism and its specific minimum 
inhibitory concentration results based on previous findings. 
 
Yeasts were identified using the Vitek 2 or API® 20C AUX (BioMerieux). Antifungal 
susceptibility testing was performed using ETESTs® or Vitek 2 (BioMerieux). The 
susceptibility values were interpreted using Clinical and Laboratory Standards Institute 
guidelines taking into account the species-specific clinical breakpoints. 
 
3.6 Data Collection  
A data collection sheet was used to record the data retrospectively. (Appendix 2). 
 
Data included paper-based hospital case notes including patient’s demographics, gestational 
age, birth weight, mode of delivery, admission diagnosis, underlying and associated conditions, 
use of central venous catheters and peripherally inserted central catheters (PICC), use of total 
parenteral nutrition, feeding, mechanical ventilation, maternal HIV status, antibiotic 
administration and surgical or invasive procedures.  
 
The maternal HIV status included antiretroviral treatment and CD4 counts where available and 
Neonatal HIV-PCR test results. 
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The universal birth HIV PCR testing programme was introduced in 2015 by the WHO in order 





The outcome was documented as discharged or as a poor outcome if the neonate demised during 
the current admission. 
 
Empirical treatment 
Neonates received penicillin G or ampicillin and gentamicin as first-line therapy or cefotaxime 
and ampicillin if meningitis was suspected as per unit policy. Empirical treatment for 
healthcare-associated infections was piperacillin-tazobactam and amikacin, with escalation to 
meropenem in suspected meningitis cases. 
 
Prematurity was defined according to WHO definition: 
Normal weight at term delivery is 2500–4200 g 
Low birth weight (LBW) is defined as a birth weight of an infant less than 2500 grams 
Very low birth weight (VLBW) is defined as a birth weight of an infant less than 1500 g 
Extremely low birth weight (ELBW), is defined as a birth weight of an infant which is less than 
1000 g  
 
The WHO classification was used for gestational age: 
Full Term is 38–41 weeks,  
Moderately preterm is 32–37 weeks 
Very Preterm 28-32 weeks  
Extremely preterm is less than 28 weeks 
 
3.8 Inclusion and Exclusion critera 
Inclusion criteria: 
- All neonates (days 1 - 28) admitted to KEH nursery for > 24 hours that were suspected 
of having infection/sepsis by the clinician were eligible for enrolment in the study. 
Sepsis was defined as nonspecific symptoms and signs of infection accompanied by 
bacteraemia or positive culture from a sterile site in the first 28 days of life. Neonates 
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with suspected sepsis who had blood culture, CSF, sputum or endotracheal aspirates 
sent to the National Health Laboratory Service (NHLS) microbiology laboratory, were 
included in the study. 
 
Exclusion criteria: 
- No consent obtained 
- Neonates with severe congenital or chromosomal abnormalities will be excluded from 
the study. 
- < 24 hours stay in the nursery 
 
The following organisms were considered to be contaminants:  
1. Micrococcus species  
2. Bacillus species  
3. Corynebacterium species  
4. Streptococcus viridans  
 
We chose to exclude Coagulase-negative staphylococcus in our analysis despite current 
literature implicating it as a cause of LOS. Determining clinical significance is problematic. 
Coagulase negative staphylococcus (CoNS) is a known blood culture contaminant, and it 
requires repeat positive cultures to establish significance. 
 
3.9 Statistical Analysis 
Data was captured in Ms Excel spreadsheet and loaded into R Statistical computing software 
for analysis. Simple descriptive statistics and inferential statistics were used for data analysis. 
The data consisted of categorical variables. The descriptive statistics included counts and 
percentage frequencies only. The descriptive statistics were further visualised using simple and 
multiple bar charts. A component bar chart was used to visualize the susceptibility of the 
Klebsiella pneumoniae. Pareto charts were also used to present the prevalence of organisms in 
blood cultures. The bivariate association between the categorical variables was assessed using 
either the Chi-square test and Fisher's exact test depending on the cross-tabulations' cell 
distribution. Fisher's exact test was specifically applied where the expected frequency of at least 
one of the cross-tabulation cells was less than 5%. 
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Univariate and multiple logistic regression was applied to assess the risk factors associated with 




CHAPTER FOUR: RESULTS 
4.1 Characteristics of Study Population, Clinical attributes and Interventions  
4.1.1 Characteristics of the Study population  
The study population comprised of 276 neonates. Neonates with suspected sepsis who had 
blood culture, CSF, sputum or endotracheal aspirates sent to the National Health Laboratory 
Service (NHLS) microbiology laboratory, were eligible. Consent was obtained from 314 
mothers, but 38 neonates were excluded. The flow diagram shows how the sample size was 
reached. (Figure 1) 
 













Eligble : 925   
Consent: 314
Final : 276                             
 Contaminants: 1066 
 Staphylococcus spp: 2042 





There was an almost equal proportion of patients, 49.3% (n = 136) that were HIV-unexposed 
and 50.7% (n = 140) that were HIV-exposed (Table 1). There were more male than female 
neonates in both groups – 58.1% vs 41.9% for HIV-unexposed and 55% vs 45% in the HIV-
exposed group. (Table 1) Eighty-eight percent of the neonates were born inside the healthcare 
facility, and eleven percent were out-born either at home or another facility. More neonates 
were delivered via caesarean section in both the HIV-exposed (47.9% vs 40.7%) and unexposed 
(47.1% vs 41.2%) in-borns. The proportions of gender (p = 0.605) and delivery modes (p = 
0.962) were not significantly different between the groups. 
 
Antenatal care was documented for the majority of the mothers. Prematurity was the most 
common admission diagnosis, and the major clinical presentation was respiratory distress. 
Twenty-six neonates were seropositive for other concurrent congenital infections including 
Syphilis, Cytomegalovirus, Rubella and Parvovirus.  
 
CD4 counts were documented for 81 of HIV-positive mothers. Median CD4 cell count was 534 
cell/mm3 with 59% having a CD4 cell count >350/mm3. The universal birth HIV PCR testing 
programme was introduced in 2015 by the WHO to diagnose HIV-infected neonates as early 
as possible and initiate ART. Of the 140 exposed neonates, 28 had no HIV PCR performed at 
birth as it was only introduced into the standard of care in late 2015 at KEH. One hundred and 
















Table 1. Study population characteristics by HIV exposure and outcome 






Sex   0.605  
Female 57 (41.9%) 63 (45.0%)  120 (43.5%) 
Male 79 (58.1%) 77 (55.0%)  156 (56.5%) 
Delivery   0.962  
Normal Vaginal Delivery 56 (41.2%) 57 (40.7%)  113 (40.9%) 
Caesarian section 64 (47.1%) 67 (47.9%)  131 (47.5%) 
Out-born 16 (11.8%) 15 (10.7%)  31 (11.2%) 
Missing 0 (0%) 1 (0.7%)  1 (0.4%) 
Gestation    <0.001  
Term (>37 weeks) 54 (39.7%) 28 (20.0%)  82 (29.7%) 
Moderately pre-term (32-37weeks) 21 (15.4%) 46 (32.9%)  67 (24.3%) 
Very pre-term (28-32 weeks) 45 (33.1%) 48 (34.3%)  93 (33.7%) 
Extremely pre-term (<28 weeks) 16 (11.8%) 18 (12.9%)  34 (12.3%) 
Weight group   <0.001  
AGA >2500g 54 (39.7%) 26 (18.6%)  80 (29.0%) 
LBW <2500g 19 (14.0%) 18 (12.9%)  37 (13.4%) 
ELBW <1000g 41 (30.1%) 44 (31.4%)  85 (30.8%) 
VLBW <1500g 22 (16.2%) 52 (37.1%)  74 (26.8%) 
The p-values are based on non-missing cases only(tableStack). 
 
4.1.2 The association between HIV exposure and clinical attributes 
Majority of the neonates 194/276 (70%) in this study, were born preterm. HIV-exposure was 
found to be associated with prematurity (p <0.001) and low birth weight (p <0.001). The most 
notable differences for gestation was a higher proportion of Term neonates in the HIV-
unexposed 39.7% (54/136) as compared to the HIV-exposed 20.0% (28/140).  
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Mortality was higher in the HIV-exposed neonates (10% vs 6.6%) (p=0.309) although it was 
not statistically significant. (Table 2) 
  
Table 2. Clinical presentation and outcome by HIV exposure 





MAS  20 (14.7%) 9 (6.4%) 0.026 29 (10.5%) 
Respiratory symptoms 100 (73.5%) 106 (75.7%) 0.677 206 (74.6%) 
Meningitis  6 (4.4%) 4 (2.9%) 0.538 10 (3.6%) 
Hepatosplenomegaly 3 (2.2%) 3 (2.1%) 1.000 6 (2.2%) 
NEC 4 (2.9%) 3 (2.1%) 0.720 7 (2.5%) 
Outcome: Demised 9 (6.6%) 14 (10.0%) 0.309 23 (8.3%) 
The p-values are based on non-missing cases only(tableStack). 
4.1.3 The association between HIV exposure and Interventions 
Respiratory interventions included intermittent positive pressure ventilation (IPPV) and nasal 
continuous positive airway pressure (CPAP). More HIV-exposed babies required ventilation 
by IPPV (51.8% vs 40.9%) and CPAP (50.4% vs 41.6%). Interventions, including IPPV and 
umbilical artery catheterisation were associated with poor neonatal outcome p=0.006 and 
p=0.022, respectively. (Table 3) 
 
Table 3. Clinical attributes and Interventions by the outcome 





Meningitis symptoms 7 (2.8%) 3 (13.0%) 0.042 10 (3.6%) 
NEC 4 (1.6%) 3 (13.0%) 0.014 7 (2.5%) 
IPPV 111 (43.9%) 17 (73.9%) 0.006 128 (46.4%) 
UAC 56(22.1%) 10(43.5%) 0.022 66(23.9%) 
 
Risk factors associated with poor outcome were analysed and adjusted for HIV, sex and weight 
group. (Table 4) 
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Table 4. Risk factors associated with Outcome 
 OR ( univariable) OR ( multivariable) 
Extremely Pre-term  
(<28 weeks) 
3.28 (1.01-11.05, p=0.047) 0.64 (0.04-14.25, p=0.768) 
NEC 9.34 (1.74-45.27, p=0.005) 12.10 (1.29-122.51, p=0.030) 
Meningitis 5.25 (1.07-20.54, p=0.023) 0.58 (0.20-1.64, p=0.299) 
IPPV 3.62 (1.45-10.32, p=0.009) 2.83 (0.81-11.87, p=0.120) 
UAC 2.71 (1.10-6.48, p=0.026) 1.60 (0.49-5.11, p=0.426) 
 
Neonates that were ventilated with IPPV were 3.62 times more likely to have a poor outcome. 
After controlling for the other risk factors like HIV exposure, sex and weight, the likelihood of 
death decreased to 2.8X. 
 
4.2 Microbiology Results 
There were 133 cerebrospinal fluid samples, 276 blood cultures and 121 endotracheal aspirates 
received for microbiological workup. Poly-microbial infections were found in blood cultures 
and the endotracheal aspirates. 
 
4.2.1 Blood cultures 
Of the 276 blood cultures received, bacterial growth occurred in 222 of the samples. The most 
common isolate causing bloodstream infections in the unit was Klebsiella pneumoniae (Figure 
2). This was followed by gram-positive bacteria including Group B Streptococcus, 
Staphylococcus aureus and Enterococcus spp. Coagulase-negative staphylococci (CoNS) and 




Key Note: NG – no growth 
Figure 2. Profile of organisms from blood cultures 
 
In the HIV-unexposed neonates, Klebsiella pneumoniae and Staphylococcus aureus were found 
to be the predominant organisms isolated while in the HIV-exposed neonates Klebsiella 
pneumoniae and Group B Streptococcus were found. (Figure 3) Other Gram-negative bacteria 
included Acinetobacter spp. and Enterobacter cloacae, which were similar in both groups. E. 





Key Note: NG – no growth 
Figure 3. Distribution of the top 60% of blood culture isolates 
 
When analysed by birth weight, Klebsiella pneumoniae was the main cause of sepsis in HIV-
unexposed infants for all weight categories. (Figure 4) However, the spectrum of the pathogens 
was different among the HIV-exposed infants. For the HIV-exposed neonates with normal birth 
weight Group B Streptococcus was the most common bacteria isolated while in the low birth 
weight neonates Klebsiella pneumoniae was predominant. Enterococcus spp. followed by 
Candida spp. were the main causes of sepsis in the HIV-exposed VLBW.  
 
Klebsiella pneumoniae and Staphylococcus aureus, were predominant in the HIV-unexposed 
ELBW neonates, while Klebsiella pneumoniae and Enterococcus spp. were found in the HIV- 





Figure 4. Blood culture results stratified by birth weight 
 
4.2.2 Profile of Pathogens in Early Onset Sepsis vs Late-Onset Sepsis 
Early Onset Sepsis 
From the bloodstream infections (BSI), there were 66 cases of culture-confirmed EOS, of which 
25/197(13%) organisms were in the HIV-unexposed, and 41/197(21%) in the HIV-exposed. 
(Table 5) For HIV-exposed infants with early-onset sepsis, GBS was the most common 
organism. In the unexposed neonates, GBS and Klebsiella pneumoniae were both found to be 
predominant. Overall for EOS, Gram-positive bacteria were found to predominate in both HIV-
exposed and unexposed neonates 15/25(60%) for unexposed and 29/41(71%) in exposed) and 
27 
included GBS, Staphylococcus aureus and Enterococcus spp. Candida spp. was isolated in two 
exposed neonates with EOS. 
 

















Escherichia coli 7(3.6) 0(0) 0(0) 2(2.8) 5(8.3) 
Klebsiella pneumoniae 59(30) 8(32) 4(9.8) 28(39.4) 19(31.7) 
Enterobacter species 7(3.6) 1(4) 3(7.3) 1(1.4) 2(3.3) 
Acinetobacter species 20(10) 1(4) 2(4.9) 9(12.7) 8(13.3) 
Serratia marcescens 6(3) 0(0) 1(2.4) 4(5.6) 1(1.7) 
Psuedomonas aeruginosa 1(0.5) 0(0) 0(0) 0(0) 1(1.7) 
Group B Streptococcus 31(15,7) 8(32) 21(51) 2(2.8) 0(0) 
Staphylococcus aureus 27(13.7) 5(20) 4(9.8) 11(15.5) 7(11.7) 
Enterococcus species 25(12.7) 2(8) 4(9.8) 9(12.7) 10(16.7) 
Candida Species 13(6.6) 0(0) 2(4.9) 4(5.6) 7(11.7) 
Aspergillus 1(0.5) 0(0) 0(0) 1(1.4) 0(0) 
      
 
Late-Onset Sepsis 
In infants with late-onset sepsis, the Gram-negative bacilli accounted for 80/131(61 %) of the 
organisms. Klebsiella pneumoniae was the most common in both HIV-exposed and unexposed. 
Staphylococcus aureus and Enterococcus spp. were the predominant gram-positive organisms 
with only two cases of GBS recorded. (Table 5) 
 
In the HIV-unexposed neonates with LOS, Klebsiella pneumoniae and Staphylococcus aureus 
were the most common bacteria isolated in BSI followed by Acinetobacter spp and 
Enterococcus spp. Serratia marcescens was predominantly found in the HIV-unexposed 
neonates with LOS. 
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In HIV-exposed neonates with LOS, Klebsiella pneumoniae and Enterococcus spp were the 
most common bacteria isolated, followed by Acinetobacter spp and Staphylococcus aureus. 
Among the 13 isolates of Candida spp. found, 4/13(31%) occurred in HIV-unexposed neonates, 
and 7/13(54%) in HIV-exposed neonates. 
 
4.2.3 Antibiotic susceptibility 
Gram-positive organisms 
Gram-positive susceptibilities were performed using the Vitek 2 system. The tested antibiotics 
included Ampicillin, Clindamycin, Cloxacillin, Erythromycin, Gentamicin, Linezolid and 
Vancomycin (Table 6). 
 











Ampicillin 31(100) NA 10(40) 
Clindamycin 28(90)  10(37) 0(0) 
Cloxacillin NA 7(26) NA 
Erythromycin 28(90)  9(33) 0(0) 
Gentamicin NA 12(44) NA 
Linezolid 31(100) 27(100) 25(100) 
Vancomycin 31(100) 27(100) 24(96) 
Key Note: NA – not applicable 
 
All the GBS isolates were susceptible to penicillin, ampicillin, linezolid and vancomycin. 
Resistance to erythromycin and clindamycin was found in 3/31(10%) of the isolates. 
 
Among the Enterococcus isolates, 9/25(36%)were E faecalis that were all susceptible to 
ampicillin. Fifteen of the twenty-five (60%) were E faecium that were resistant to ampicillin. 
All Enterococcal isolates were susceptible to linezolid and vancomycin apart from one isolate 
of E gallinarum, which was expected.  
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All 27(100%) isolates of S. aureus were susceptible to Vancomycin and Linezolid. 
Susceptibility to Cloxacillin was found in 7/27(26%) of the isolates, and they were also 
susceptible to Clindamycin, Erythromycin and Gentamicin. The remaining 20/27(74%) of the 
Staphylococcus aureus were methicillin-resistant with 17/27(63%) and 18/27(67%) of these 
isolates resistant to Clindamycin and Erythromycin respectively. Gentamicin susceptibility was 
found in 12/27(44%) of the isolates.  
 
The susceptibility patterns of Gram-negative bacteria are presented in Table 7. 
 
Table 7. Antimicrobial susceptibility profile Gram-negative bacteria  

















Ampicillin 0(0) 0(0) 0(0) 0(0) 0(0) 
Amoxicillin-clavulanate 15(25) 0(0) 7(100) 0(0) 0(0) 
Piperacillin- tazobactam 25(42) 3(15) 7(100) 0(0) 5(71) 
Cefotaxime 17(29) 2(10) 3(43) 0(0) 0(0) 
Imipenem 47(80) 3(15) 7(100) 6(100) 7(100) 
Meropenem 46(78) 3(15) 7(100) 6(100) 7(100) 
Gentamicin 13(22) 5(25) 3(43) 6(100) 5(71) 
Amikacin 46(78) 13(65) 7(100) 6(100) 7(100) 
Ciprofloxacin 34(58) 5(25) 5(71) 6(100) 7(100) 
Tigecycline 57(97) 17(85) 7(100) NA NA 
Key Note: NA – not applicable 
All isolates were resistant to ampicillin. Resistance to third-generation cephalosporins occurred 
in more than half of the isolates.  
 
All isolates of E. coli were fully susceptible to piperacillin-tazobactam, amikacin, imipenem 
and meropenem. Three of the seven isolates (43%) were susceptible to cefotaxime and 
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gentamicin while five isolates (71%) showed ciprofloxacin susceptibility. Four (57%) isolates 
were ESBL producing. 
 
All isolates of Serratia marcescens and Enterobacter spp. were susceptible to meropenem, 
ciprofloxacin, gentamicin and amikacin. 
 
Acinetobacter spp. showed limited susceptibility to gentamycin (25%), amikacin (25%), 
ciprofloxacin (25%), piperacillin-tazobactam (15%), Cefotaxime (10%), Imipenem (15%) and 
Meropenem (15%). Eighty-five percent of the isolates were susceptible to tigecycline. 
 
Susceptibility of Klebsiella pneumoniae 
There were 59 isolates of Klebsiella pneumoniae. Of these, 12(20%) were fully susceptible to 
cefotaxime (3rd generation cephalosporins), amikacin, ciprofloxacin, and the carbapenems- 
imipenem, and meropenem. Susceptibility to other antibiotics included 83% to gentamicin, 
75% to piptazobactam), and 75% to amoxicillin clavulanate. 
 
Thirty-four (57%) of the 59 isolates were ESBL producers, and 13(22%) were carbapenem-
resistant. They were all resistant to Ampicillin, and 78% were resistant to Gentamicin. The 
overall prevalence of ESBL producing Klebsiella pneumoniae was 56%. High resistance rates 
were observed for the beta-lactam agents amoxicillin clavulanate (82%) and piperacillin-
tazobactam(52%). Gentamicin resistance was found in 91% and ciprofloxacin resistance in 
41%. 
 
Multi-drug resistance was documented for 13/59 (22.3%) of the Klebsiella pneumoniae 
isolates. Among the Carbapenem-resistant Klebsiella pneumoniae, only 23% showed 







Figure 5. Antibiotic resistance patterns of susceptible, ESBL producing and Carbapenem-
resistant Klebsiella spp. 
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Candida parapsilosis accounted for 11/13(84%) of the cases of neonatal candidemia. C 
albicans and C glabrata were the other species found (8% each). Fluconazole resistance was 
found in 4/11(36%) of the C parapsilosis isolates. Voriconazole susceptibility testing was 
introduced in 2015, and resistance was detected in one isolate. 
 
4.2.4 Cerebrospinal fluid 
CSF cultures were conducted on 133 neonates (48%). Of these, four yielded positive results 
(4/133 = 3%). One CSF was from an HIV-unexposed neonate which cultured a Serratia 
marcescens. The other three that were positive were from HIV-exposed neonates, two with 
ESBL producing Klebsiella pneumoniae and one neonate was positive for Mycobacterium 
tuberculosis. From the 31 neonates that had GBS on blood culture, CSF cultures were sent from 
20 neonates. All 20 specimens had no growth on culture. 
 
4.2.5 Endotracheal aspirates 
A total of 121 respiratory samples were sent, 37 (30.5%) had no bacterial growth. Sixteen were 
from HIV- exposed and 21 from HIV-unexposed neonates. Eighty-four were culture-positive, 
of which eight had more than one organism and all organisms were included in the analysis. 
(Table 5) Thirty-seven of the culture-positive samples were from HIV-unexposed neonates, 
and 47 from HIV-exposed neonates. 
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Gram-negative organisms    
Klebsiella pneumoniae 17(35) 12(29) 29(32) 
Acinetobacter spp. 9(19) 10(24) 19(21) 
E. coli 5(10) 5(12) 10(11) 
Enterobacter cloacae 0(0) 3(7) 3(3) 
Serratia marcescens 0(0) 2(4) 2(2) 
Pseudomanas aeuruginosa 1(2) 0(0) 1(1) 
Stenotrophomonas maltophilia 0(0) 1(2) 1(1) 
Gram-positive organisms    
Staphylococcus aureus 4(8) 3(7) 7(8) 
Staphylococcus spp. 5(10) 2(4) 7(8) 
GBS 1(2) 0(0) 1(1) 
Enterococcus spp. 1(2) 1(2) 2(2) 
Bacillus spp. 1(2) 0(0) 1(1) 
Fungal    
Candida spp. 3(6) 2(4) 5(6) 
Mycobacterium tuberculosis  1(2) 1(2) 2(2) 
 
The pathogen distribution was similar for HIV-exposed and unexposed neonates. Gram-
negative bacteria (65/90)(72%) were the most commonly isolated organisms in the 
endotracheal aspirates. The commonest Gram-negative organism was Klebsiella pneumoniae 
(29/90)(32%), followed by Acinetobacter spp. (19/90)(21%), and E. coli (10/90)(11%). (Table 
8) Gram-positive organisms constituted 20% (18/90) of the organisms isolated. Staphylococcus 
aureus and Staphylococcus spp. predominated amongst the Gram-positive organisms. Yeasts 
were cultured from five neonates and Mycobacterium tuberculosis from two neonates.  
 
Resistance among the endotracheal isolates was high for both Gram-positive and Gram-
negative bacteria. The majority of the Klebsiella pneumoniae (93%) isolated displayed 
resistance to first and second-line antibiotics used in the unit. ESBL-producing strains were 
found in 16/29 (55%) of the Klebsiella pneumoniae, and 11/29 (37%) were resistant to 
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Carbapenems. Of the 17 HIV-exposed neonates with Klebsiella pneumoniae, 10/17 (58%) were 
ESBL-producing, and 6/17 (35%) were Carbapenem-resistant. Findings were similar in the 




Figure 6. Sensitivity of Klebsiella pneumoniae from Endotracheal aspirates 
 
All Acinetobacter spp were XDR, and 40% of E. coli were ESBL producers. 
 
Amongst the Gram-positive bacteria, all Staphylococcus aureus were methicillin-resistant 
Staphylococcus aureus (MRSA) strains, and all Coagulase-negative staphylococcus were 
cloxacillin resistant from both HIV-exposed and HIV-unexposed neonates. All Candida 
isolates from ETAs were Fluconazole resistant. Three of the Candida spp were from HIV-
exposed neonates and two from unexposed. Mycobacterium tuberculosis isolated from the 
HIV-exposed and unexposed neonates were sensitive to standard anti-Tb treatment regimes. 
One exposed neonate from a mother with an antenatal diagnosis of MTB had both, an 
endotracheal aspirate and a positive CSF. The second neonate required IPPV from birth. Both 















CHAPTER FIVE: DISCUSSION  
In the present study, we describe the organisms responsible for neonatal sepsis in HIV-exposed 
and unexposed infants in a tertiary neonatal unit in Durban. GBS was the predominant cause of 
early-onset neonatal sepsis in HIV-exposed neonates while GBS and Klebsiella pneumoniae 
was found in the HIV-unexposed neonates. Klebsiella pneumoniae was the most common 
pathogen in both groups with a high proportion being ESBL producing and some resistant to 
carbapenem antibiotics for late-onset neonatal sepsis.  
 
Evidence suggests that HIV-exposed infants experience greater mortality and hospitalisation 
than unexposed due to infectious morbidity (Slogrove et al., 2016). We found that HIV 
exposure was associated with a poor outcome, especially in the VLBW and ELBW neonates. 
Mortality risks were increased if they presented with meningitis or necrotising enterocolitis and 
had interventions like umbilical artery catheterization and mechanical ventilation.  
 
In early-onset sepsis, we found GBS to be the predominant organism in HIV-exposed neonates. 
Similar findings were noted by Slogrove et al. where the risk Group B Streptococcus and 
Streptococcus pneumoniae was greater in HIV-exposed infants and a Belgium study that 
reported an increased incidence of neonatal GBS in HIV-exposed neonates (Slogrove et al., 
2016; Dauby, Chamekh, Melin, Slogrove & Goetghebuer, 2016). In the HIV-unexposed group, 
GBS, as well as Klebsiella pneumoniae, were present. Studies have reported a predominance 
of Gram-positive organisms in EOS. Velaphi et al. (2019) found Group B streptococcus, 
Viridans streptococcus and Enterococcus species as the most common bacteria in EOS and 
Escherichia coli in 10% of cases in a study done in Soweto. In a study in Khayelitsha, South 
Africa, the most frequent pathogens in neonates <28 days of age (n=40) were Group B 
Streptococci (20/40, 50.0%), S. aureus (7/40, 17.5%) and E. coli (6/40, 15.0%) (Crichton et al., 
2018). There were no E. coli isolated as a cause of EOS in this study. 
 
The epidemiology and microbiology of LOS are very diverse and depends on geographic areas 
and socio-economic factors (Giannoni et al., 2018). High-income countries have reported a 
prevalence of Gram-positive organisms, including coagulase-negative staphylococci and 
Staphylococcus aureus. A 10-year review from Queensland Australia showed that 73% of LOS 
was due to Gram-positive organisms of which 39.8% was coagulase-negative staphylococci. In 
comparison, the United Kingdom's surveillance data found an equal proportion of Gram-
36 
positive and Gram-negative bacteria, with 10% being fungal (Dong, Speer & Glaser, 2018). 
The predominant organisms were S aureus, E. coli and Candida albicans (Cailes et al., 2018). 
We chose to exclude CONS in this study due to difficulty in determining its significance. 
Repeat blood cultures are needed to establish the significance of CONS in neonatal sepsis 
(Coetzee et al., 2017). 
 
In late-onset sepsis, Klebsiella pneumoniae was the predominant pathogen in both HIV-
unexposed and exposed neonates followed by Staphylococcus aureus in HIV-unexposed and 
Enterococcus spp. in HIV-exposed neonates. A retrospective review at a tertiary care Neonatal 
Unit in Johannesburg, South Africa, also found Gram-positive and Gram-negative infections 
prevalent in LOS. However, the Gram-negative bacteria, especially E. coli and K. pneumoniae, 
accounted for more deaths (Ballot et al., 2019). In this study, Gram-negative bacteria accounted 
for 60% of the LOS and included Klebsiella pneumoniae, Acinetobacter spp., E. coli, and 
Serratia marcescens. This increase in Gram-negative pathogens is consistent with other reports 
from low- and middle-income countries, noting a significant change in pathogens, particularly 
the emergence of A. baumannii LOS (Ballot, Nana, Sriruttan & Cooper, 2012). Li et al. (2018) 
found that greater than 50 % of LOS in preterm infants with poor outcome was due to Gram-
negative bacteria (Li et al., 2018).  
 
Eighty-five percent of the Klebsiella pneumoniae in our study displayed resistance to first-line 
antibiotics with 61% being ESBL producing and 23 % carbapenemase-producing. Thirteen 
neonates cultured carbapenem-resistant Klebsiella pneumoniae from the blood culture with four 
neonates having the organism on ETA. Sixty-two percent of these were in HIV-unexposed 
neonates and most occurred when there was a carbapenem-resistant Klebsiella pneumoniae 
outbreak in the unit. All carbapenem-resistant Klebsiella pneumoniae infected neonates had a 
good outcome in this study. The case fatality rate in neonates with carbapenem-resistant 
Klebsiella pneumoniae vary with 33.3% reported in the Johannesburg Neonatal Unit while a 
study in Egypt reported 44.3% (Ballot et al., 2019, Nour et al., 2017). Mortality was 
significantly associated with lower birth weight, necrotising enterocolitis and mechanical 
ventilation (Ballot et al., 2019). In this study, carbapenem-resistant Klebsiella pneumoniae 
infected neonates had a good outcome despite 69% being ventilated. Sixty-two percent of these 
infections occurred in HIV-unexposed neonates. 
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The other Gram-negative bacteria also showed resistance to the first-line antibiotics in the 
study. Acinetobacter spp. isolated from 17 neonates with LOS were all MDR. Fifty-seven 
percent of the E. coli were ESBL positive, and five neonates had sepsis due to Serratia 
marcescens, a known AmpC producer. Viswanathan et al. (2014) reported that almost one-third 
(32.1%) of positive blood cultures in the NICU were caused by glucose-non-fermenting Gram-
negative bacilli, of which Acinetobacter species was the most common organism and 50% of 
those isolates were MDR (Viswanathan et al., 2014). A study in Nepal reported that 77% of 
their isolates being Gram-negative with Klebsiella species and Enterobacter species being most 
common (Pokhrel, Koirala, Shah, Joshi & Baral, 2018). Greater than 50% of the bloodstream 
infections in a Neonatal Unit in Johannesburg were due to MDR organisms with Klebsiella 
pneumoniae being the most common isolate (Ballot et al., 2019).  
 
Resistance was also high amongst the Gram-positive organisms. Staphylococcus aureus and 
Enterococcus spp. were causes of LOS in both HIV-unexposed and exposed neonates. Of the 
18 Staphylococcus aureus isolates, 89% were MRSA. Nineteen neonates had Enterococcus 
species of which 63% were the more resistant Enterococcus faecium. MRSA is a significant 
pathogen, particularly in preterm low birth weight neonates (Dong et al., 2018). Colonisation 
is associated with a 24.2 times increased risk of infection (Washam, Woltmann, Haberman, 
Haslam & Staat, 2017). Risk factors for colonisation include very preterm infants (born <32 
weeks’ gestation) and VLBW infants (born <1,500 g) (Washam et al., 2017). In our study, 50% 
of neonates with MRSA bacteraemia were below 1500g, but all had a good outcome.  
 
Enterococcus spp. was the second most common pathogen in LOS found in HIV-unexposed 
and exposed neonates. The majority were Enterococcus faecium isolated in neonates were low 
birth weight. Six with VLBW and three neonates with ELBW. Enterococci species have 
evolved from harmless commensals to becoming important pathogens associated with 
nosocomial infection. In recent years, the incidence of Vancomycin-Resistant Enterococci in 
neonatal ICUs has become a growing concern (Shantala, Nagarathnamma, Pooja, Harsha & 
Karthik, 2014). Fortunately, we had only one case of VRE in the study with a favourable 
outcome. 
 
Candida bacteraemia was found in 11 neonates with LOS and two with EOS. The majority 
were VLBW with three ELBW. Nine of these neonates were exposed of which two demised. 
Low birth weight infants are at risk of candidaemia due to their immature immune system being 
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unable to eliminate the pathogen (Fu et al., 2018). Other risk factors, especially in VLBW, 
include mechanical ventilation, medical devices like catheters, broad-spectrum antibiotic use 
and total parenteral nutrition (Fu et al., 2018). In this group, most of the candidaemia occurred 
in HIV-exposed neonates, of which 23% were on TPN, and 69% had umbilical catheters. 
Mortality occurred in two neonates. 
 
Candida parapsilosis was the dominant species in this study, found in 85% of the newborns. 
This is consistent with findings from other centres. C. parapsilosis caused 54.2% neonatal BSIs 
in a Johannesburg hospital (Ballot, Bosman, Nana, Ramdin & Cooper, 2013). An Italian study 
reported 58.5% Candida rates parapsilosis compared to 34.1% C albicans in their neonatal 
intensive care unit (Caggiano et al., 2017).  
 
Due to high invasive candidiasis rates, fluconazole prophylaxis is currently recommended in 
neonates with birth weights <1000g (Pappas et al., 2016). Laboratory-based surveillance of 
neonatal and adult candidaemia in public and private hospitals in South Africa between 2009–
2010 found a dominance of C. parapsilosis with only 37% susceptible to fluconazole and 
voriconazole (Govender et al., 2016). The rising resistance to fluconazole is a concern, and 31% 
of the isolates were fluconazole-resistant in this study.  
 
Mycobacterium tuberculosis was isolated in two neonates. Prematurity and low birth weight 
have been described in neonates with congenital MTB (Bekker, Schaaf, Draper, Kriel & 
Hesseling, 2016). A recent prospective study conducted in Cape Town on HIV-infected and 
uninfected pregnant and postpartum women with TB found 3% of the newborns infected while 
in the pre-antiretroviral era, Adhikari et al. (2011) reported the incidence of 15% (Bekker et al. 
2016; Adhikari et al., 2011). The improvement of MTB diagnosis with the introduction of the 
molecular platforms like the Xpert MTB/RIF will assist with the early detection in pregnant 
women. 
 
The HIV-exposed neonates were more likely to have lower birth weight and were of lower 
gestation than the unexposed neonates in this study. This is in keeping with other studies that 
show that HIV-positive pregnant women have significantly more preterm deliveries than their 
HIV-negative counterparts (Naidoo et al., 2016). Parekh et al. (2011) found an increased risk 
of very-small-for-gestational-age among HIV-exposed infants in Botswana (Parekh et al., 
2011). A meta-analysis by Peng-Lei Xiao et al. (2015) found similar findings. HIV-infected 
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women are at higher risk of having a low birth weight infant or a preterm delivery infant 
compared with HIV-uninfected women (Xiao et al., 2015).  
 
IPPV was an independent risk factor for mortality. A significant proportion of the neonates 
admitted to NICU required ventilation. From the neonates that demised in this study, 73.9% 
(17/23) were on IPPV. Survival rates of 64% and 67.9% have been described from other similar 
studies in low-middle income countries (Trotman, 2006; Karthikeyan & Hossain, 2002). 
Weight <2500g and gestation <34 weeks are some of the predictors of mortality in ventilated 
neonates (Iqbal et al., 2015). 
 
The significance of Coagulase negative staphylococci from endotracheal aspirates is not well 
established, but several studies have described its presence. Madan, Meyer & Amortequi (1988) 
studied autopsy specimens of lung tissue from neonates that had demised from congenital 
pneumonia. The most frequently isolated organism was Staphylococcus epidermidis (18%), 
Group B Streptococcus (13%), E. coli (9%) and Ureaplasma urealyticum (9%) (Madan et al., 
1988)  
 
Resistance amongst ventilated patients was high in both the HIV-unexposed and exposed. The 
majority of the neonates on IPPV had Gram-negative bacteria on endotracheal aspirates. Gram-
positive bacteria were Staphylococcus aureus and coagulase-negative staphylococcus. Both 
were resistant to cloxacillin which meant use of vancomycin or linezolid. Gram-negative 
bacteria included ESBL producing and carbapenemase resistant Klebsiella pneumoniae, ESBL 
producing E. coli and MDR Acinetobacter. Despite the presence of highly resistant organisms, 
the main challenge was the diagnosis of VAP. Currently, the Centers for Disease Control and 
Prevention (CDC) guidelines do not offer algorithms for neonates. There is a lack of a gold 
standard case definition and diagnostic tests for intubated newborns. ETA cultures are a 
problem due to low sensitivity (Claassen & Keenan, 2019). The aetiology of ventilator-
associated pneumonia is often polymicrobial, and differentiating colonisation from infection is 
difficult (Claassen & Keenan, 2019). Due to the strong association between IPPV and mortality, 
mechanisms to reduce VAP in the unit is vital. This warrants looking at introducing Quality 




The study highlights the high rate of resistant organisms among HIV-exposed and unexposed 
neonates in the unit. Increase in resistance was seen in both Gram-positive and Gram-negative 
bacteria. For EOS, the organisms were susceptible, and the unit’s ampicillin and gentamicin 
policy provided good empirical coverage. However, for LOS, most pathogens were resistant to 
the second-line antibiotics, and Carbapenems and Vancomycin provided the greatest in-vitro 
cover for bloodstream infections in the unit. 
 
Strategies to reduce the MDR rates include infection-prevention and control (IPC) programmes 
and antimicrobial stewardship programmes. Basic infection-prevention measures are currently 
practised, but specialised unit-specific protocols may be needed given the procedures 
undertaken like umbilical catheter placement, surfactant administration, incubator and radiant 
warmer care, preparation, and storage maternal and donor breast milk that is unique to neonatal 
environments. Regular training of all staff and the use of care bundles can improve the quality 
of NICU practices and ensure adhering to evidence-based guidelines and prevent HAIs. 
 
Antimicrobial stewardship programmes are essential to help conserve antibiotics and delay the 
progression of AMR. Regular audits are required to track antimicrobial usage and monitor 
resistance, and this will help with the development of unit-specific antimicrobial treatment 
protocols based on local susceptibility data. Due to the increasing incidence of hospital-
acquired infections and antimicrobial resistance seen in neonatal units, The SA Neonatal Sepsis 
Task Force was launched (Dramowski et al., 2020). The focus will be on preventing and 




CHAPTER SIX: CONCLUSION  
GBS remains the primary cause of EOS in HIV-exposed and unexposed neonates and is 
sensitive to the current first-line antibiotics, ampicillin and gentamicin used in the unit. For 
LOS, 60% were caused by Gram-negative bacteria found in both HIV-exposed and unexposed 
neonates. These included ESBL producing Klebsiella pneumoniae, Carbapenem-resistant 
Klebsiella pneumoniae and MDR Acinetobacter spp. The antibiotic policy for treatment of LOS 
in the unit needs to review as well as infection prevention and control and antimicrobial 




Limitation of study is the absence of non-culture based methods for the detection of sepsis. The 
microbiological workup of CSF, ETA and blood culture only detected culturable organisms. 
The use of PCR-based assays to detect the 16S ribosomal RNA in clinical specimens may help 
detect non-culturable organisms.  
 
Twenty-eight neonates had no HIV PCR performed at birth and we were unable to characterise 
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APPENDIX 1: STUDY PROTOCOL 
Spectrum of organisms and outcome of neonatal infections in HIV exposed and unexposed 




Supervisor: Prof K Mlisana 
Co-supervisor: Prof M Adhikari 




The aim of the study is to: 
- establish the aetiology and susceptibility patterns of organisms responsible for neonatal 
infections in HIV exposed and unexposed newborns with suspected sepsis at King Edward VIII 
Hospital neonatal unit 
- identify risk factors that are associated with these neonatal infections. 





 To investigate the organisms isolated from blood cultures, respiratory and cerebrospinal 
fluid samples responsible for neonatal sepsis in that unit.  
 
 To establish the antibiotic susceptibility profile of these organisms to antimicrobial 
agents used. 
 
 To assess the risk factors associated with neonatal sepsis 
 
 To determine outcome of these infections – primary outcome being mortality and 




Neonatal sepsis is a major cause of infant morbidity and mortality. The main causes of death in 
the neonatal period are prematurity, perinatal asphyxia, birth trauma, congenital abnormalities 
and infections respectively. Common infections include septicaemia, meningitis, respiratory 
infections, diarrhoea and neonatal tetanus.1  
 
The immature immune system in the neonate exposes them to higher risk of infections.  Whilst 
babies are born without endogenous microbial flora they rapidly become colonised with 
microbes encountered in the maternal genital tract and their immediate postnatal environment.2 
As the immature immune system is unable to provide a robust defence against microbes, the 
risk of developing invasive infections increases. 
 
Maternal risk factors for neonatal sepsis include chorioamnionitis, prolonged rupture of 
membranes and meconium-stained amniotic fluid. Tuberculosis (TB) and HIV are also well-
recognised risk factors for maternal and infant mortality and morbidity. KwaZulu-Natal has 
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been described as having one of the highest rates of HIV and Tuberculosis in South Africa.3 
Congenital TB carries a high risk of infant death, with reported mortality rates of up to 38%. 
Postnatal acquisition of TB infection by young infants is also associated with a high risk of 
disseminated and rapidly fatal TB disease.4   
 
Highly active antiretroviral therapy (HAART) has markedly improved the health and the long-
term prognosis of HIV-infected patients and reduced the risk for mother-to-child transmission 
(MTCT) of the virus. This has led to an increase in the number of HIV-exposed uninfected 
(HEU) infants. 3 These infants may be more susceptible to infections than infants born to HIV-
uninfected mothers but data on the outcomes of these newborns is lacking. King Edward VIII 
(KEH) hospital is a tertiary hospital with over 7000 births /annum. The prevalence of HIV at 
the KEH antenatal clinic is around 40% and 35-40% of the admissions to nursery are HIV 
exposed neonates (personal communication: Dr R Singh, KEH Neonatal Unit). For effective 
management of these patients, establishing the spectrum of commonly infecting organisms and 
risk factors for disease is vital. 
 
Neonatal practices vary in different countries and these geographical differences are reflected 
in the diverse patterns of neonatal sepsis. The pathogen distribution, epidemiology and 
resistance patterns are different for developing and developed countries.  A review by Vergnano 
et al. found that in the developing world, Gram-negative bacteria such as Klebsiella 
pneumoniae, E coli, Serratia marscesens, Pseudomonas aeruginosa, and Salmonella spp and 
the Gram positive organisms, Staphylococcus aureus and coagulase-negative Staphylococcus 
(CoNS) are the predominant pathogens. 5 In the developed countries Group B Streptococcus 
(GBS) remains the most frequent pathogen in term infants, and E. coli the most significant 
pathogen in preterm infants with early onset sepsis.6  
 
The data on aetiology of neonatal sepsis in South Africa is diverse, but remains limited. In a 
large study with a cohort of over 8000 mother-baby pairs delivered at a public hospital in 
Soweto, maternal and neonatal factors associated with neonatal sepsis and perinatal death  were 
assessed.7 There were 289 cases of early-onset sepsis (EOS) and of the ten percent (29/289) 
that were culture confirmed, GBS was the most common pathogen. Escherichia coli was the 
leading cause of late-onset sepsis (LOS) followed by GBS.  
 
Blood culture audits done at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) 
neonatal unit found varying aetiology over time. An audit done in 2002-2003 found gram 
negative bacilli to be the leading organisms in EOS and coagulase-negative Staphylococcus in 
LOS 8, while a review of blood culture isolates in 2009-2010 found S. agalactiae as the major 
cause of EOS. 9 Current data on the aetiology of neonatal sepsis in KZN is lacking. 
 
Isolation of microorganisms from blood culture or cerebrospinal fluid has remained the most 
definitive way of making a diagnosis of infection in a neonate. Urine samples are often 
unreliable in a newborn as they are usually bag specimens that are frequently contaminated. 
Adjunctive tests like the haematological indices and acute phase reactants have been used but 
are not sufficiently sensitive and specific to exclude or confirm the diagnosis of neonatal 
sepsis.10 
 
Blood cultures remain the mainstay of investigation of potential sepsis in infants. The 
sensitivity of the culture methods is frequently low, due to the concomitant antibiotic therapy, 
or to the combination of small blood sample volume and low colony counts.10 Despite 
improvements in automated blood culture systems, results of blood culture can be delayed by 
up to 48 hours. 
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Pathogens can be directly identified from patient samples or after initial growth in blood 
cultures.  Although the major benefit of a molecular test is speed, none have shown to have a 
sensitivity and specificity sufficient to replace standard blood culture techniques, which carry 
the additional important advantage of antibiotic susceptibility. (10) The cost-effectiveness and 
clinical impact of molecular assays still need evaluation but has the potential of being an 
adjunctive to blood cultures.  
 
Bacterial organisms causing neonatal sepsis have developed increased drug resistance to 
commonly used antibiotics, making management a challenge for both the public and private 
health sectors. 8 These multidrug resistant organisms such as Klebsiella spp, Pseudomonas spp, 
and Acinetobacter spp ,decrease therapeutic options resulting in serious challenges in poorly 
resourced countries where access to alternative antibiotics is severely limited. This resistance 
is fuelled by poor infection-control practices and gross inappropriate use of antibiotics. The 
powerful selective pressure of inappropriate and prolonged antimicrobial use favours the 
emergence and amplification of resistance in hospital nurseries.2  
 
Neonatal sepsis is associated with significant morbidity and mortality justifying prompt 
initiation of empirical antibiotic therapy. Knowledge of the common pathogens causing 
septicemia in neonates and their local antimicrobial susceptibility is essential to select 
appropriate antimicrobial treatment. 11 We therefore aim to prospectively observe the risk 
factors, aetiology and susceptibility profile of the organisms causing neonatal infections and 
document the outcome of these infections in HIV exposed and unexposed infants at KEH  This 
will help evaluate the empiric guidelines currently used in the unit and guide the development 
of future studies exploring  the use of  rapid microbiological and  molecular techniques to enable  
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A prospective descriptive study:  Routine samples sent to the microbiology laboratory from 
infants with suspected sepsis will be analysed. Their clinical and demographic details, risk 




The study population will comprise of HIV exposed and unexposed infants with suspected 
sepsis that are admitted to KEH nursery for > 24hours. Written informed consent will be 




As per the unit policy, the following samples will be taken during a septic workup: 
-Blood culture, CSF ( if clinically indicated ) and ETA for ventilated patients. 
-FBC and CRP 




Statistical projection for sample size is 370 based on delivery rate ,suspected sepsis rate and the 
40% maternal HIV prevalence. 
 
Inclusion criteria: 
- All neonates (days 1 - 28) admitted to KEH nursery for > 24 hours that are suspected of 
having infection/sepsis by the clinician will be eligible for enrolment in the study 
 
Exclusion criteria: 
- No consent obtained 
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- Neonates with severe congenital or chromosomal abnormalities will be excluded from 
the study. 
- < 24 hours stay in nursery 
 
Data collection methods: 
 
All blood cultures, cerebrospinal fluids and respiratory samples received from neonates 
admitted to the unit during the study period will be included in the study. 
 
Sample Collection, Handling and Transport: 
-Blood Cultures: Using aseptic technique about 1 – 3ml of blood will be inoculated directly 
into BACT/ALERT PF Paediatric culture vials and transported to the KEH Microbiology 
Laboratory for subsequent processing. 
 
Bottles will be loaded into the BACT/ALERT 3D Microbial Detection System which is a fully 
automated blood culture system. 
 
Positive blood cultures will be removed from instrument and microscopy and culture 
performed.  
 
Blood cultures will be considered negative if there is no growth after continuous incubation for 
up to 7 days  
-Cerebrospinal fluid: All lumbar punctures will be performed using aseptic technique and at 
least 0.5ml of CSF in a sterile additive free tube will be sent to laboratory. Once received, the 
macroscopic appearance will be recorded.  Microscopy will include a cell count and gram stain. 
The sediment will be cultured onto blood, chocolate and MacConkey agar plates and incubated. 
-Respiratory Samples: will include sputum specimens, endotracheal aspirates, 
bronchoalveolar lavage fluid and gastric aspirates for TB.                                              The most 
purulent portion of the specimen will be used for gram stain and innoculated onto blood, 
chocolate and MacConkey agar plates. Gastric aspirates will be cultured for TB as per 
laboratory standard operating procedures.  
-Whole Blood Sample: the sample will be left to stand for 15-30 min for blood to clot. The 
clot will be removed by centrifuging at 1,000-2,000 x g for 10 minutes in a refrigerated 
centrifuge. The supernatant – which is the serum will be transferred into a clean polypropylene 
tube using a Pasteur pipette. The serum will be apportioned into 0.5ml aliquots and stored at –
20°C for future workup. 
Culture and Identification:  
Innoculated plates will be incubated for 18 hours at 35ºC and then inspected for bacterial 
growth. Bacterial colonies will be definitively identified using the VITEK 2 system 
(bioMérieux SA, France). Antimicrobial susceptibility testing will be done following Clinical 
Laboratories Standard Institute (CLSI) recommendations.  
Definitions: 
A blood culture will be considered contaminated if 1 or more of the following organisms are 
identified: 
 -Coagulase-negative Staphylococcus spp 
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 -Viridans streptococci 
 -Micrococcus spp 
 -Bacillus spp 
 -Corynebacterium spp 
 
Primary outcome: Mortality 
Secondary outcome: Morbidity  
 
Clinical and demographic data : 
 
Clinical and demographic data for each patient including date and place of birth, mode of 
delivery, gestational age, Apgar score,  HIV status, TB exposure, feeding options, specific 
clinical diagnosis, clinical signs of sepsis, antibiotic treatment and outcome will be obtained by 
attending paediatrician and captured on the datasheet below. 
Datasheet: see appendix 
 
Data Analysis: 
Data will be entered and analysed in The SPSS software version 21. 
Simple descriptive statistics and inferential statistics will be used for data analysis. Frequence 
distribution tables and graphs (bar/pie) will be constructed for categorical variables. Measures 
of central tendency and dispersion will be calculated for continuous variables. Multivariate 
statistical methods will be used to assess the risk factors associated with neonatal sepsis. 
 
Study location: 




Written, signed, informed consent will be obtained from parent/guardian/caregiver. 
A study number given to each participant will be used on the datasheet and laboratory forms. 






APPENDIX 2: DATA SHEET FOR NEONATAL MICRO STUDY 
NEONATAL DATA: 
Study no. :____________                Date of Birth:__________ 
Birth weight:________Kg                Gestational  Age:___________    SEX:____________ 
Mode of Delivery:    NVD  / BBA  /  C/S       Meconium Stained Liquor : N / Y  :   I /II / III 
RH :___________  WR:____________ 
APGAR Score :   1min___________5 min_________ 
Respiratory Distress at Birth: _____      SRT :_______ 
Meningitis ______ Hepatosplenomeg__________NEC___________ 
IPPV:   Y / N    Duration:______                CPAP:   Y / N    Duration:______ 
UV line:  Y / N  Duration:_____     UA line: Y / N  Duration:______    PICC line:  Y / N  
Duration:______ 
TPN :   Y / N   Duration: ____ 
HIV : unexposed  ____  exposed _____  infected_____ uninfected_______ 
TB :  exposed  Y/N       infected Y/N         
Lab investigations: 
Sample Date AG no. Results 
FBC 
diff 
   
CD4    
U&E    
CRP    
Whole blood     
Blood culture    






   
Urine    





Feeding:   Breastfed :  Y / N    Donor : Y /N   Formula :  Y /N 
Bld T/f : Y/N     Steroids : Y/N  duration__________ 
Antibiotics:  Y /N                                       
1.____________________    Duration:________                
2.____________________   Duration:________                
3.____________________    Duration:________                
Antifungal : Y / N 
1.___________________      Duration:________ 
HAART :  Y / N 
1.____________________    Duration:________                
2.____________________   Duration:________     
Outcome:  ____________    Discharged : __________ 
Demise :_________Cause :________  Age :   Day _______ 
MATERNAL DATA:   
Antenatal:  PROM :  Y / N   Duration:__________  Pyrexia : Y / N    Chorioamnionitis : Y / N 
Antibiotics: Y / N    Name : ____________________ Duration: ________________ 
HIV________   HAART: ___________ Duration:___________   CD4 :___________ 














My name is Dr Prasha Mahabeer from Department of Microbiology, National Health 
Laboratory Service at King Edward Hospital. 
 
You are invited to be part of a research study. The study involves looking at the germs or 
bacteria that cause disease in newborns - babies that are less than 28 days old. The point of this 
research is to find out what are the common bacteria/germs that cause different types of 
infections and to see if the antibiotics that are being used to treat them will help to cure the 
infection.  
 
This study is expected to study 370 newborns that are admitted to the King Edward hospital 
Nursery with supposed infection. It will involve everyday procedures. Samples that will be used 
for the study are the tests that are done daily by the doctors looking after your baby. Extra tests 
will only be done if clinically needed. The length of time of your involvement if you choose to 
enroll and remain in the study will be the period of time your newborn stays in the nursery. You 
will not remain longer in the hospital for the study. 
 
The study is funded by______________ 
 
We hope that the study will have the following benefits: better knowledge of germs currently 
causing disease in newborns and which antibiotics are effective to treat them. 
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number_____). 
 
In the event of any problems or concerns/questions you may contact the researcher at : 
Department of Microbiology  
King Edward Hospital  
Tel: 031 360 3184/91 
Email: mahabeerp2@ukzn.ac.za  
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or the UKZN Biomedical Research Ethics Committee, contact details as follows:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban 
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
Participation in this research is voluntary and you may withdraw participation at any point. In 
event of refusal/ withdrawal, you will not incur any loss of treatment or benefit to which your 
baby is normally entitled. 
 
To ensure confidentiality, your baby will be allocated a study number. That study number will 




APPENDIX 4: INFORMED CONSENT FORM 
 
I……………………………………………………………… mother/legal guardian of 
……………………………………….., hereby give my permission to Dr Prasha Mahabeer to 
use my and my child’s clinical information, laboratory specimens and radiological imaging in 
the study on “Spectrum of organisms and outcome of neonatal infections in HIV-exposed and 
unexposed newborns at a tertiary care hospital in KZN”. 
 
I understand that the study will be sent to a Journal for publication. It will not include any 
information that will allow me or my child to be identified. 
 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any 
time without affecting any treatment or care that my child would be entitled to. 
 
If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher. 
 
If I have any questions or concerns about my rights as a study participant, or if I am concerned 
about an aspect of the study or the researchers then I may contact: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban 
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
 
My consent is voluntary. The information has been explained to me in my own language and I 




____________________     ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date   
 
 
____________________   _____________________ 





INFORMED CONSENT FORM FOR STORAGE OF HUMAN BIOLOGICAL 
MATERIAL FOR RESEARCH PURPOSES1 
BIOMEDICAL RESEARCH ETHICS COMMITTEE, UNIVERSITY OF 
KWAZULU- NATAL 
 
[Spectrum of organisms and outcome of neonatal infections in HIV-exposed and 
unexposed newborns at a tertiary care hospital in KZN.] 
 
The Document consists of two parts: 
 
1. Information Document  






My name is Dr Prasha Mahabeer from Department of Microbiology, National Health 
Laboratory Service at King Edward Hospital. 
You are invited to be part of a research study. The study involves looking at the germs or 
bacteria that cause disease in newborns - babies that are less than 28 days old. 
The purpose of this study is to find out what are the common bacteria/germs that cause different 
types of infections in babies and to see if the antibiotics that are being used to treat them at the 
moment are useful. 
The study will look at specimens and blood taken from your baby. These may include sputum, 
fluid around the spine or blood, depending on where the infection is. 
I, Dr Prasha Mahabeer from the Department of Microbiology at King Edward Hospital, 
NHLS/UKZN, would like your permission to store blood and any bacteria/germs cultured from 
those specimens for future testing. 
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USE AND STORAGE  
The reason for storing the samples is to do further tests on it at a later stage. The samples will 
be stored in a freezer at -350C in the Department of Microbiology at King Edward Hospital for 
5 years and thereafter discarded in a safe manner. My supervisor Prof K Mlisana and I, Dr 
Prasha Mahabeer will only have access to these samples. 
 
BENEFITS  
There are no direct benefits of the study to your baby but this study will improve the future 
treatment of babies with infections. The information obtained from the stored samples may be 
used for teaching, public health surveillance, research, to generate new knowledge, for 




There are no risks to having your baby’s sample stored. 
 
CONFIDENTIALITY 
To ensure confidentiality, your baby will be allocated a study number. That study number will 
be used on all documentation, reports and storage of samples. The results of future tests will 
not go into your baby’s medical records. 
  
PARTICIPANTS RIGHTS 
You may not agree to have your baby’s sample stored and used for future research. This will 
not affect your baby’s participation in the study. Please feel free to tell me if there is 
something that you don’t want your baby’s sample used for or if you don’t want their sample 
used at all. 
 
You may withdraw permission at anytime – by contacting me: Dr Prasha Mahabeer at 
Department of Microbiology at King Edward Hospital, Tel: 031 360 3184. 
 
You may ask any questions about any part of the information provided above.  
 
Any research which uses the sample/s will have been approved by the University’s Ethics 
Committee. 
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The sample/s collected during 2014-2019 may be stored at Microbiology Department 
at King Edward Hospital. 
 
The sample/s [blood and isolates] to be stored and used in future research for the 
specific purposes of this study [Spectrum of organisms and outcome of neonatal 
infections in HIV-exposed and unexposed newborns at a tertiary care hospital 
in KZN] approved by BREC 
 
The sample/s [blood and isolates] to be stored and used in future research of any type 
which has been approved by BREC. 
 
 
The sample/s[blood and isolates] to be used for teaching, quality assurances, public 
health surveillance, clinical audit, publications and presentations approved by BREC 
 
 
CERTIFICATE OF CONSENT 
 
In the light of the information that I have received, and having had the opportunity to ask 
questions that have been answered, and if any of the biological material [specify, i.e. blood, 
isolates] I, parent/guardian of __________________________________ have provided for this 
research project: Spectrum of organisms and outcome of neonatal infections in HIV-
exposed and unexposed newborns at a tertiary care hospital in KZN, is unused or leftover 
or additional samples have been provided, I agree to participate in the research study and 
consent to the following: 
 
                            Yes           No 
The samples [blood and isolates] to be disposed of lawfully, immediately     
 
The sample/s [blood and isolates] to be disposed of lawfully after_5_ years. 
. 
The sample/s [blood and isolates] to be stored for _5__years 
 
AND if the sample is to be stored I consent to the following: 
                  










AND                                
                                                                                                                                             
 
 
I want my child’s identity to be removed from my sample/s [blood and isolates]   
             
I want my child’s  identity to be kept with my samples [blood and CSF]                                         
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 AND               Yes        No 
 
I am willing to be re-contacted by the researcher/s about possible future use of my child’s 
sample/s in the future 
 





I have read the information, or it has been read to me. I have had the opportunity to ask questions 
about it and my questions have been answered to my satisfaction. I consent voluntarily to have 
my samples stored in the manner and for the purpose indicated above. I have been informed of 
my right to withdraw my consent to the storage and/or use of my samples at any time and 
without giving any reason and without prejudice to myself or my child’s treatment. 
 
I have been informed that I will be given information from the research team concerning the 
progress and general results of the research studies upon my explicit request. I have also been 
informed that they will not communicate any individual results to me. 
 
Name of Participant__________________   
 
Signature of Participant ___________________ 
 
Date ___________________________ 
 Day/month/year    
 
If illiterate 
A literate witness must sign (if possible, this person should be selected by the participant and 
should have no connection to the research team). Participants who are illiterate should 
include their thumb-print as well.  
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I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness_____________________                                           Thumb print of 
participant 
 
Signature of witness _____________________ 
 
 
Date ____________________  Time____________________ 
                Day/month/year 
  
STATEMENT BY THE RESEARCHER/PERSON TAKING CONSENT 
 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands. 
I confirm that the participant was given an opportunity to ask questions about the nature and 
manner of storage of the samples, and all the questions asked by the participant have been 
answered correctly and to the best of my ability. I confirm that the individual has not been 
coerced into giving consent, and the consent has been given freely and voluntarily.  
  
 A copy of this Informed consent form has been provided to the participant. 
 
Name of Researcher/person taking the consent________________________  
   
Signature of Researcher /person taking the consent__________________________ 
 
Date ___________________________ Time_______________________________ 
  






APPENDIX 5: BIOMEDICAL RESEARCH ETHICS COMMITTEE OF 
UNIVERSITY OF KWAZULU-NATAL – LETTER OF APPROVAL 
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APPENDIX 6: BIOMEDICAL RESEARCH ETHICS COMMITTEE OF 
UNIVERSITY OF KWAZULU-NATAL – RECERTIFICATION 
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APPENDIX 9: RESULTS 
Interventions by HIV exposure 






IPPV   0.088  
No 80 (58.8%) 68 (48.6%)  148 (53.6%) 
Yes 56 (41.2%) 72 (51.4%)  128 (46.4%) 
CPAP   0.112  
No 80 (58.8%) 69 (49.3%)  149 (54.0%) 
Yes 56 (41.2%) 71 (50.7%)  127 (46.0%) 
Umbilical vein   0.620  
No 74 (54.4%) 72 (51.4%)  146 (52.9%) 
Yes 62 (45.6%) 68 (48.6%)  130 (47.1%) 
Umbilical artery   0.668  
No 105 (77.2%) 105 (75.0%)  210 (76.1%) 
Yes 31 (22.8%) 35 (25.0%)  66 (23.9%) 
PICC   0.097  
No 122 (89.7%) 133 (95.0%)  255 (92.4%) 
Yes 14 (10.3%) 7 (5.0%)  21 (7.6%) 
TPN   0.293  
No 108 (79.4%) 118 (84.3%)  226 (81.9%) 
Yes 28 (20.6%) 22 (15.7%)  50 (18.1%) 
Feeding   0.790  
Breast 125 (91.9%) 124 (88.6%)  249 (90.2%) 
Formula 7 (5.1%) 8 (5.7%)  15 (5.4%) 
Missing 4 (2.9%) 8 (5.7%)  12 (4.3%) 
Transfusion   0.513  
No 97 (71.3%) 104 (74.3%)  201 (72.8%) 
Yes 39 (28.7%) 35 (25.0%)  74 (26.8%) 
Missing 0 (0%) 1 (0.7%)  1 (0.4%) 
The p-values are based on non-missing cases only(tableStack). 
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APPENDIX 10: TURNITIN ORIGINALITY REPORT 
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